Reaching Consensus on the Adoption of Oncology Biosimilars

Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of CME/CE/CPE-certified ClinicalThought™ commentaries!

Rowena N. Schwartz, PharmD, BCOP

ClinicalThought

How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.

Rowena N. Schwartz, PharmD, BCOP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.2 Nursing contact hours Pharmacists: 0.25 contact hours (0.03 CEUs) Released: November 14, 2018 Expiration: November 13, 2019
Provided by Postgraduate Institute for Medicine
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com

This activity is supported by an educational funding donation provided by
Amgen

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?